Abstract:Vancomycin utilisation has increased dramatically in the last 10 years due to the increasing clinical significance of infections with methicillin-resistant staphylococci. Recent studies have focused on characterising the disposition of vancomycin in patients and assessing the relationship between serum concentrations and therapeutic as well as adverse effects.Although vancomycin is not appreciably absorbed from the intact gastrointestinal tract, several recent case reports have documented the attainment of therapeutic and potentially toxic vancomycin serum concentrations following oral administration to patients with pseudomembranous colitis. The disposition of parenterally administered vancomycin has been best characterised by a triexponential model. The half-life of the initial phase (t½π) is approximately 7 minutes, that of the second phase (t½α) is approximately 0.5 to 1 hour, while the terminal elimination half-life (t½β) ranges from 3 to 9 hours in subjects with normal renal function. The volume of the central compartment (Vc) in adults is approximately 0.15 L/kg while the steady-state volume of distribution (Vdss) ranges from 0.39 to 0.97 L/kg. More than 80% of a vancomycin dose is excreted unchanged in the urine within 24 hours after administration, and the concentration of vancomycin in liver tissue and bile has been reported to be at or below detection limits. Vancomycin renal clearance approximates 0.5 to 0.8 of simultaneously determined creatinine or 125I-iothalamate clearances, suggesting that the primary route of renal excretion is glomerular filtration. Recently, non-renal factors such as hepatic conjugation have been proposed as an important route of vancomycin elimination. However, these data are difficult to reconcile with other studies showing minimal non-renal clearance of vancomycin in subjects with end-stage renal disease. As yet, the disposition of vancomycin in patients with hepatic disease has not been adequately defined.Only limited data are available regarding the concentrations of vancomycin in biological fluids other than plasma. The penetration of vancomycin into cerebrospinal fluid (CSF) in patients with and without meningitis has been quite variable. Although early studies suggested that adequate CSF concentrations may not be achieved in subjects with uninflamed meninges, more recent investigations have reported contradictory results. Therapeutic concentrations of vancomycin, i.e. greater than 2.5 mg/L, have, however, been reported in ascitic, pericardial, pleural and synovial fluids. Tissue concentrations of vancomycin have exceeded simultaneous serum concentrations in heart, kidney, liver and lung specimens.The disposition of vancomycin in paediatric and geriatric patients appears to be primarily related to the degree of renal function. However, there is some evidence of altered tissue binding and/or tissue distribution in geriatric patients. Since significant interpatient variability has been reported, further investigation will be required to substantiate dosing recommendations for these patient populations. Vancomycin clearance is decreased and the elimination half-life progressively prolonged in association with declining glomerular filtration rate, but the volume of distribution at steady-state is not significantly correlated with declining renal function. Although marked variability in vancomycin clearance within a defined range of renal function has been observed, highly significant relationships between vancomycin clearance and creatinine clearance have been reported and may be utilised for the adjustment of dosage in this patient population. Haemodialysis provides no significant contribution to total body clearance of vancomycin, while haemoperfusion has produced prompt and sharp declines in vancomycin serum concentrations. Peritoneal dialysis clearances of vancomycin are markedly lower than those observed during haemodialysis or haemoperfusion. However, due to the longer course of this mode of dialysis, contribution to total body clearance may be significant for some patients.Although early reports suggested that vancomycin therapy was frequently associated with adverse events, several recent reports have indicated that vancomycin is extremely safe. Nephrotoxicity has been observed in approximately 5% of patients and is associated with trough serum vancomycin concentrations of 30 mg/L or greater. The combination of an aminoglycoside and vancomycin may significantly increase the risk of nephrotoxicity. A causal relationship between attainment of peak vancomycin serum concentrations of 25 to 50 mg/L and/or trough concentrations of 13 to 32 mg/L and ototoxicity has been reported. Ototoxicity may be reversed, if not prevented, by close monitoring of vancomycin serum concentrations. The remaining adverse reactions which have been reported do not appear to be related to vancomycin dosage or serum concentrations.The prospective design of vancomycin dosage regimens would appear to be warranted in adults with impaired renal function, elderly patients, morbidly obese patients, and paediatric patients. Although the pharmacokinetic profile of vancomycin is best described by a 2- or 3-compartment model, the collection of a sufficient number of serum concentrations to perform these characterisations in individual patients is not practical or cost-justified in routine clinical practice. Therefore an approach similar to that used for the aminoglycoside antibiotics would appear to be most practical.

Telavancin Pharmacokinetics and Pharmacodynamics in Patients with Complicated Skin and Skin Structure Infections and Various Degrees of Renal Function

Population Pharmacokinetics of Vancomycin in Kidney Transplant Recipients: Model Building and Parameter Optimization.

Pharmacokinetics of Vancomycin in Healthy Korean Volunteers and Monte Carlo Simulations to Explore Optimal Dosage Regimens in Patients with Normal Renal Function

Clinical Pharmacokinetics of Vancomycin

Initial Dosage Regimens Of Vancomycin For Chinese Adult Patients Based On Population Pharmacokinetic Analysis

Daptomycin Dosage Optimization in Renal Impairment Using Model-Informed Precision Dosing

Beyond One-Size-Fits-All: Tailoring Teicoplanin Regimens for Normal Renal Function Patients Using Population Pharmacokinetics and Monte Carlo Simulation

Population Pharmacokinetics and Dose Optimization of Vancomycin in Critically Ill Children

Population Pharmacokinetics and Dosing Optimization of Vancomycin in Pediatric Liver Transplant Recipients

Vancomycin population pharmacokinetics for adult patients with sepsis or septic shock: are current dosing regimens sufficient?

Population Pharmacokinetics and Model-Based Dose Optimization of Vancomycin in Sudanese Adult Patients with Renal Impairment

Population Pharmacokinetics and Pharmacodynamics of Vancomycin in Pediatric Patients With Various Degrees of Renal Function

Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam

Development and Assessment of Vancomycin Dosing Utilizing AUC/MIC Protocol in Patients With End-Stage Renal Disease (ESRD) on Intermittent Hemodialysis (IHD)

Population Pharmacokinetic Modeling and Dose Optimization of Vancomycin in Chinese Patients with Augmented Renal Clearance

Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations

Population pharmacokinetics and dosing optimization of vancomycin in infants, children and adolescents with augmented renal clearance

Pharmacokinetics and dosing of vancomycin in patients undergoing sustained low efficiency daily diafiltration (SLEDD-f): A prospective study

Implementation of vancomycin AUC/MIC dosing vs traditional trough dosing and incidence of acute kidney injury at a rural community hospital

Influences of renal function descriptors on population pharmacokinetic modeling of vancomycin in Chinese adult patients

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Evaluate In Vitro Susceptibility Test Interpretive Criteria for Ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae